Key result
Prazosin initially reduced systemic and pulmonary pressures at rest and during exercise, but these haemodynamic effects were significantly attenuated after 12 weeks of sustained treatment.
Why the study?
Does prazosin improve haemodynamics during rest and exercise in patients with severe ischaemic left ventricular failure?
Observational (n=12)
Does prazosin improve haemodynamics during rest and exercise in patients with severe ischaemic left ventricular failure?
The acute haemodynamic benefits of prazosin in severe heart failure are significantly attenuated after sustained treatment.
Initial haemodynamic benefits of prazosin may attenuate with chronic use in ischaemic LV failure; leaves open long-term efficacy questions.
To ascertain the immediate pharmacodynamic and long-term haemodynamic effects of prazosin in chronic ambulant heart failure, measurements were made during sitting, standing, and walking in 12 patients with severe ischaemic left ventricular failure before and after their first dose of prazosin (2 mg) and in six of these patients after a further 12 weeks of sustained treatment (2 mg tds). When first added to treatment with digoxin and frusemide, prazosin was followed within an hour by substantial reductions in systemic arterial, pulmonary arterial, and pulmonary venous pressures in both postures at rest and also during walking. These changes were significantly attenuated after continued treatment. Cardiac output while sitting and standing at rest was reduced in both instances but the response to exercise was unchanged. The pharmacodynamic effects of prazosin in heart failure are explicable in terms of blockade of alpha1 adrenoceptors in arterial resistance and venous capacitance vessels augmented perhaps by lessening of reflex vasoconstriction secondary to the reduction in pulmonary venous pressure. The cause of the attenuation of the acute haemodynamic effects of the drug during sustained treatment is unknown.
No takes yet. Share an insight, caveat, or question.
Silke et al. (1981) conducted an observational in Severe ischaemic left ventricular failure (n=12). Prazosin vs. Baseline (before treatment) was evaluated on Haemodynamic effects (systemic arterial, pulmonary arterial, and pulmonary venous pressures). Prazosin initially reduced systemic and pulmonary pressures at rest and during exercise, but these haemodynamic effects were significantly attenuated after 12 weeks of sustained treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: